News | February 28, 2010

Patients Prefer Iohexol Contrast Over Diatrozoate

February 28, 2010 - Patients expressed a statistically significant preference for the taste of iohexol over diatrozoate, a feature that is especially beneficial for very ill patients whom have trouble tolerating the taste of contrast agents, concluded a recent study.

Researchers from Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Missouri and the Milton S. Hershey Penn State Medical Center conducted a study comparing the tolerability of iodine-based oral contrast agents, Omnipaque (iohexol) and Gastroview (meglumine sodium diatrizoate). The purpose of the study was to compare the efficacy and patient acceptance of iohexol verus meglumine sodium diatrozoate for abdominal and pelvic CT scans.

Researchers presented on February 21 at the Abdominal Radiology Course Meeting held by the Society of Gastrointestinal Radiology and The Society of Uroradiology in Orlando.

The study also concluded that:

- There was no statistically significant difference between the two agents in the incidence of adverse reactions.

- The extent and density of GI tract opacification also were similar between the two groups.

- The cost of the two agents is comparable given the current low cost of low osmolar contrast agents.

For more information: www.mir.wustl.edu

Related Content

Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa